What are the current frontline treatment options for newly diagnosed pediatric AML patients with high FLT3/ITD allelic ratio and IDH2 mutation?  

This is an interesting question. Since IDH2 mutations are so rare in pediatrics, we don't yet have enough information to determine their impact on the outcome. Also, targeted agents for IDH2 mutations are still in early investigational phases for pediatrics, so I would not necessarily include enasid...